Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 7, 2009, Pages 1277-1278

  Angelucci, Francesco ^a   Ricci, Valerio ^a,b   Martinotti, Giovanni ^a,b   Caltagirone, Carlo ^c,d   Bria, Pietro ^b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Department of Clinical and Behavioural Neurology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PALIPERIDONE; PAROXETINE; SERTRALINE;

ADULT; ALCOHOLISM; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DRUG ABUSE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY HISTORY; HUMAN; LETTER; MALE; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; HUMANS; ISOXAZOLES; MALE; OBSESSIVE-COMPULSIVE DISORDER; PYRIMIDINES; SCHIZOPHRENIA;

EID: 69349101031     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.06.014     Document Type: Letter

References (15)

1. Atmaca M., Kuloglu M., Tezcan E., and Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17 (2002) 115-119
2. Balant-Gorgia A.E., and Balant L.P. Therapeutic drug monitoring in psychiatry: relevance during the drug treatment of psychiatric disorders. CNS Drugs 4 (1995) 432-453
3. Bloch M.H., Landeros-Weisenberger A., Kelmendiv B., Coric V., Bracken M.B., and Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11 (2006) 622-632
4. Citrome L.P. Paliperidone: quo vadis?. Int J Clin Pract 61 (2006) 653-662
5. Delgado P.L., and Moreno F.A. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Br J Psychiatry Suppl 173 (1998) 21-25
6. Dolder C., Nelson M., and Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm 65 (2008) 403-413
7. Gao K., Muzina D., Gajwani P., and Calabrese J.R. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 64 (2006) 1327-1340
8. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale I. Development, use, and reliability. Arch Gen Psychiatry 46 (1989) 1006-1011
9. Matsushita M., Egashira N., Harada S., Mishima K., Mishima K., Iwasaki K., et al. Perospirone, a novel antipsychotic drug, inhibits marble-burying behaviour via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci 99 (2006) 154-159
10. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and typical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251 (2005) 238-246
11. Nemeroff C. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66 (2005) 13-21
12. Olesen O.V., Licht R.W., Thomsen E., Bruun T., Viftrup J.E., and Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20 (1998) 380-384
13. Sareen J., Kirshner A., Lander M., Kjernisted K.D., Eleff M.K., and Reiss J.P. Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder symptoms? A systematic review. J Affect Disord 82 (2004) 167-174
14. Van Nimwegen L., De Haan L., Van Beveren N., Laan W., Van den Brink W., and Linszen D. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J Clin Psychopharmacol 28 (2008) 214-218
15. Veznedaroglu B., Ercan E.S., Kayahan B., Varan A., and Bayraktar E. Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study. Hum Psychopharmacol 18 (2003) 635-640